




The relative strengths and weaknesses of CNS Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CNS Pharmaceuticals Inc compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 6.7% points. The greatest weakness of CNS Pharmaceuticals Inc is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 70% points.

The company's Economic Capital Ratio, given in the ranking table, is 131%, being 98% points below the market average of 229%.

Input Variable	Value in 1000 USD
Assets, Current	8,103
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	4,101
Liabilities, Non-Current	0
Other Assets	503
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	136
Other Revenues	0
Property and Equipment	18
Research and Development	9,772
Selling, General and Administrative Expense	6,215

Output Variable	Value in 1000 USD
Assets	8,623
Liabilities	4,101
Expenses	15,987
Revenues	0
Stockholders Equity	4,523
Net Income	-15,851
Comprehensive Net Income	-15,851
BaseVar	14,423
ECR before LimitedLiability	-94%
Economic Capital Ratio	131%